Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Rockeby Announces R&D Appointments

Rockeby Announces R&D Appointments

Australia, 10 March 2005 Rockeby biomed Limited (ASX:RBY) today announced the following appointments in the company's R&D department located in Perth.

Dr John Warmington, Director of Research & Development at Rockeby biomed (Australia) Pty Ltd will relinquish his position and assume a consultancy role as Chief Scientist with immediate effect. Dr Warmington will remain as Executive Director of Rockeby biomed (Australia) Pty Ltd and as Non-Executive Director of Rockeby biomed Limited, the ASX listed company of the Rockeby biomed Group of Companies.

Dr Warmington was instrumental in the Research & Developmental phases of Rockeby's two products namely SysCan3(r), a multi-well Elisa based hospital test kit and CanDia5(r), the world's first and only blood-based professional point of care diagnostic test kit. Dr Warmington will continue to play an important role as Chief Scientist as the company continues to commercialize new diagnostic products in the future pipeline.

Dr David Capes Ph.D, Head, Product Development, Diagnostics Division at Rockeby biomed (Australia) Pty Ltd will be promoted to Vice President - Research & Development with immediate effect. Dr Capes, was previously Director of R&D (Asia-Pacific) with Becton Dickinson where he oversaw a staff of 35 and a multi-million dollar budget. He has more than 20 years' pharmaceutical industry experience.

Dr Capes played an important role in the last year in Rockeby's US FDA 510(k) application, the ISO and Quality Management System, and CE Mark certification processes that has enabled Rockeby to achieve ISO certification and CE Mark approval ahead of schedule.

Dr Capes will continue to conduct research and development activities in line with corporate strategies and carry out product development of new diagnostic products.

Rockeby biomed is an ASX-listed (ASX: RBY) biotechnology company engaged primarily in the research, development and marketing of products for the diagnosis and treatment of fungal infections in humans. The company's main market is that of in-vitro diagnostic testing which covers serology tests in hospitals as well as point-of-care products for use by consumers or health professionals operating outside hospitals.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>


Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>


Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>


Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>


Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news